Abstract
The integrin receptor αvβ3 has been shown to play a critical role in several distinct processes, such as angiogenesis, osteoclast-mediated bone resorption and tumor metastasis. Its expression is upregulated in newly synthesized blood vessels produced in response to a variety of tumors and purified angiogenic factors. Studies show that αvβ3 is a critical target downstream from perhaps all angiogenic factors. Proof-of-principle that αvβ3 antagonists such as monoclonal antibodies and small molecules block angiogenesis and tumor growth has been obtained in several animal models. Many endogenous inhibitors of angiogenesis such as angiostatin, endostatin and tumstatin seem to work through the αvβ3 receptor further emphasizing the critical role of this receptor in angiogenesis. In addition, the αvβ3 receptor has been clearly implicated in several pathological processes such as rheumatoid arthritis, osteoporosis, and metastasis of prostate cancer to bone. Thus αvβ3 may prove to be an important target for pharmacological intervention in more than one clinical setting.
Keywords: integrin family, integrin, tumor-induced angiogenesis, alpha v beta 3
Current Drug Targets
Title: Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
Volume: 4 Issue: 2
Author(s): C. Chandra Kumar
Affiliation:
Keywords: integrin family, integrin, tumor-induced angiogenesis, alpha v beta 3
Abstract: The integrin receptor αvβ3 has been shown to play a critical role in several distinct processes, such as angiogenesis, osteoclast-mediated bone resorption and tumor metastasis. Its expression is upregulated in newly synthesized blood vessels produced in response to a variety of tumors and purified angiogenic factors. Studies show that αvβ3 is a critical target downstream from perhaps all angiogenic factors. Proof-of-principle that αvβ3 antagonists such as monoclonal antibodies and small molecules block angiogenesis and tumor growth has been obtained in several animal models. Many endogenous inhibitors of angiogenesis such as angiostatin, endostatin and tumstatin seem to work through the αvβ3 receptor further emphasizing the critical role of this receptor in angiogenesis. In addition, the αvβ3 receptor has been clearly implicated in several pathological processes such as rheumatoid arthritis, osteoporosis, and metastasis of prostate cancer to bone. Thus αvβ3 may prove to be an important target for pharmacological intervention in more than one clinical setting.
Export Options
About this article
Cite this article as:
Kumar Chandra C., Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis, Current Drug Targets 2003; 4 (2) . https://dx.doi.org/10.2174/1389450033346830
DOI https://dx.doi.org/10.2174/1389450033346830 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Importance of Melatonin and Mitochondria Interaction in Mood Disorders and Schizophrenia: A Current Assessment
Current Medicinal Chemistry Adopting Network Pharmacology for Cancer Drug Discovery
Current Drug Discovery Technologies Molecular Delivery of Plasmids for Genetic Vaccination
Current Pharmaceutical Biotechnology Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
Current Cancer Drug Targets The Infectious Etiology of Alzheimer’s Disease
Current Neuropharmacology Synthesis, Biochemical Evaluation and Rationalisation of the Inhibitory Activity of a Range of Derivatives of 2-imidazol-1-yl-1-phenyl-ethanone as Potential Novel Inhibitors of 17α-hydroxylase/17,20-lyase (P-45017α)
Letters in Drug Design & Discovery Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition The Metabolite Trimethylamine-N-Oxide is an Emergent Biomarker of Human Health
Current Medicinal Chemistry The Development of Pro-Apoptotic Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Wnt / β-Catenin Signaling Pathway as Novel Cancer Drug Targets
Current Cancer Drug Targets Editorial [Hot Topic: Cancer and Stem Cells (Guest Editor: Eiichi Tahara)]
Current Cancer Therapy Reviews Fluorescent Substrates Useful as High Throughput Screening Tools for ADAM9
Combinatorial Chemistry & High Throughput Screening Pyrrolo[2,1-c][1,4]benzodiazepine as a Scaffold for the Design and Synthesis of Anti- Tumour Drugs
Anti-Cancer Agents in Medicinal Chemistry Comparison of the Growth Curves of Cancer Cells and Cancer Stem Cells
Current Stem Cell Research & Therapy Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Natural Compounds A Weapon to Ameliorate Breast Cancer Cells: A Review
Anti-Cancer Agents in Medicinal Chemistry Design and Synthesis of a (N-Alkylaminoalkyl-Substituted)Arylalkenylamide Drug Discovery Library
Letters in Drug Design & Discovery The Endocrine Regulation of Stem Cells: Physiological Importance and Pharmacological Potentials for Cell-Based Therapy
Current Stem Cell Research & Therapy Chemotherapeutic Effects of Acridine Derivatives
Medicinal Chemistry Reviews - Online (Discontinued) MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers
Current Pharmaceutical Design